Abstract: Disclosed is an isolated nucleic acid molecule comprising a nucleotide sequence that is at least 90% identical to a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO 4, wherein the protein has an aspartic acid (Asp) at amino acid position 106 Transgenic plants comp?sing the nucleic acid have reduced or delayed softening and detenoration of fruit compared to wild-type plants Methods of genetic screening for plants having reduced or delayed softening and detenoration of fruit, isolated oligonucleotides, and a method of imparting to a plant the dfd trait are also disclosed.
Type:
Grant
Filed:
May 19, 2009
Date of Patent:
October 6, 2015
Assignees:
Cornell Research Foundation, Inc., Boyce Thompson Institute for Plant Research
Inventors:
Jocelyn Kenneth Rose, Tal Isaacson-Lustig, Julia Vrebalov
Abstract: The present invention relates to compositions and methods for analyzing and modulating (e.g., enhancing or inhibiting) protein-protein interactions. In particular, compositions and methods of the present invention find use in identifying, reconstituting and characterizing protein-protein interactions, identifying binding subunits, and drug screening. The methods and compositions of the invention may also be used to identify agents that may agonize or antagonize a protein-protein interaction (e.g., using test compounds).
Type:
Grant
Filed:
August 22, 2006
Date of Patent:
October 6, 2015
Assignees:
CORNELL RESEARCH FOUNDATION, INC., RESEARCH DEVELOPMENT FOUNDATION
Inventors:
Matthew DeLisa, George Georgiou, Dujduan Waraho
Abstract: The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
Type:
Grant
Filed:
November 8, 2013
Date of Patent:
October 6, 2015
Assignee:
CORNELL RESEARCH FOUNDATION, INC.
Inventors:
Hazel H. Szeto, Shaoyl Liu, Sunghee Cho
Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.
Type:
Grant
Filed:
May 19, 2014
Date of Patent:
September 15, 2015
Assignees:
Cornell Research Foundation, Inc., The Regents of the University of California, The United States of America represented by the Department of Veterans Affairs, Fundação Oswaldo Cruz—FIOCRUZ
Inventors:
Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
Abstract: The present invention is directed to a mutant thermostable ligase having substantially higher fidelity than either T4 ligase or Thermus thermophilus ligase. The ligase of the present invention is a mutant of a wild-type thermostable ligase having a histidine adjacent a KXDG motif, where the mutant thermostable ligase has a mutation in its amino sequence where the histidine adjacent the KXDG motif in the wild-type thermostable ligase is replaced with an arginine, and wherein X is any amino acid. The DNA molecule encoding this enzyme as well as expression systems and host cells containing it are also disclosed. The thermostable ligase of the present invention is useful in carrying out a ligase detection reaction process and a ligase chain reaction process.
Abstract: The present invention relates to a method of preventing or treating a disease caused by infection by a eukaryotic pathogen, wherein the method comprises administering an effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of a eukaryotic pathogen's adenylyl cyclase that do not substantially modulate an adenylyl cyclase of the subject. The invention also provides methods for culturing eukaryotic pathogens and methods for inducing the pathogenic state in vitro.
Type:
Grant
Filed:
January 11, 2008
Date of Patent:
August 4, 2015
Assignee:
CORNELL RESEARCH FOUNDATION, INC.
Inventors:
Lonny Levin, Jochen Buck, Leo Brizuela, Michael Pinnisi
Abstract: The present invention relates to a method of evaluating the cancer state of a subject using lecithin:retinol acyl transferase (LRAT) gene promoter methylation status. Methods of analyzing and quantifying LRAT gene promoter methylation level are also disclosed. The present invention also relates to methods of determining the prognosis for s subject having cancer by assessing LRAT mRNA expression and LRAT protein expression. Methods of cancer detection, diagnosis, prognosis, and treatment are also disclosed.
Type:
Grant
Filed:
December 19, 2007
Date of Patent:
July 28, 2015
Assignees:
Cornell Research Foundation, Inc., Sloan Kettering Institute for Cancer Research, Rutgers, The State University of New Jersey
Inventors:
Francis Barany, Yu-Wei Cheng, Philip Paty, Daniel Notterman
Abstract: The present invention relates to formulations of viable microorganisms in a water insoluble, water-absorbent substance and methods of producing formulations of viable microorganisms. Also disclosed is a method of treating plants and/or plant seeds with the formulations of the present application.
Type:
Grant
Filed:
September 7, 2006
Date of Patent:
July 28, 2015
Assignees:
Advanced Biological Marketing Incorporated, Cornell Research Foundation, Inc.
Abstract: An array of electrochemical detectors includes an array of electrodes that provide current responsive to oxidation events. Each electrode is coupled to a transistor, an amplifier coupled to an input of the transistor and having a feedback loop coupled to the electrode and providing a bias voltage to the electrode, an integrating capacitor coupled to the transistor operable to integrate charge from the electrode, and a reset switch coupled to the integrating capacitor. The amplifier may have a shared stage with other detectors. A shared buffer circuit may also provide a sampled output from multiple detectors.
Type:
Grant
Filed:
November 25, 2008
Date of Patent:
July 21, 2015
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Bradley A. Minch, Sunitha Bandla Ayers, Manfred Lindau
Abstract: The present invention relates to compositions and methods for displaying proteins and polypeptides on the surface of cells and cellular vesicles. Methods and compositions for drug and vaccine delivery using cell surface display systems of the present invention are also disclosed.
Type:
Grant
Filed:
May 21, 2008
Date of Patent:
June 9, 2015
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Matthew Delisa, Jae-Young Kim, David A. Putnam, Anne M. Doody
Abstract: Compound containing at least 15% inorganic content demonstrates liquid-like behavior and is distinct in exhibiting liquid-like behavior in the absence of solvent. In one case it is quaternary ammonium derivative of a heteropolyacid. In another case, it is a salt formed by reaction of heteropolyacid and polyethylene glycol alkylamine. In other cases, it is condensation product of oxide and quaternary ammonium cation where the balancing anion has a molecular weight greater than 200. In still other cases it is a salt formed by reaction of sulfonated silica or sulfonated fullerene and polyethylene glycol alkylamine. In still other cases, it is a neutral organic-inorganic hybrid which is PEG-functionalized silica nanoparticle or is a layered-nanoparticle obtained by hydrolytic polymerization of organosilane in nonpolar solvent.
Type:
Grant
Filed:
August 31, 2005
Date of Patent:
May 19, 2015
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Emmanuel P. Giannelis, Athanasios B. Bourlinos
Abstract: The present invention relates to a method of preventing or treating a disease caused by bacterial infection by administering an effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of bacterial adenylyl cyclase that do not substantially modulate adenylyl cyclase of the subject. The invention also provides methods for culturing bacterial pathogens and methods for inducing the pathogenic state in vitro.
Type:
Grant
Filed:
January 11, 2008
Date of Patent:
April 28, 2015
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Lonny Levin, Jochen Buck, Leo Brizuela, Michael Pinnisi
Abstract: The present invention relates to a prokaryotic host cell comprising eukaryotic glycosyltransferase activity, where the eukaryotic glycosyltransferase activity is eukaryotic dolichyl-linked UDP-GlcNAc transferase activity and eukaryotic mannosyl-transferase activity. Also disclosed is a method of producing a glycosylated protein by providing a prokaryotic host cell comprising the eukaryotic glycosyltransferase activity and culturing the prokaryotic host cell under conditions effective to produce a glycosylated protein. Another aspect of the present invention pertains to a method for screening bacteria or bacteriophages by expressing one or more glycans on the surface of a bacteria, attaching a label on the one or more glycans on the surface of the bacteria or on the surface of a bacteriophage derived from the bacteria, and analyzing the label in a high-throughput format.
Type:
Grant
Filed:
January 5, 2009
Date of Patent:
April 7, 2015
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Matthew DeLisa, Cassandra Guarino, Thomas Mansell, Adam Fisher
Abstract: The present invention relates to a method of producing a heterologous protein or polypeptide having phytase activity in a yeast system. The invention also provides proteins having phytase activity which have increased thermostability. Yeast strains which produce a heterologous phytase and the vectors used to produce the phytase are also provided.
Abstract: A method for assessing risk of losing a transplanted organ by a patient having an episode of acute rejection of the transplanted organ is described. The method includes obtaining from the patient a cell sample from the transplanted organ or peripheral blood, determining a level of FOXP3 in the cell sample, and correlating the level with the risk of loss of the transplanted organ, wherein, compared to a control level, a significantly greater level of FOXP3 in the cell sample from the transplanted organ or a significantly lower level of FOXP3 in the cell sample from the peripheral blood correlates with a decreased risk of loss of the transplanted organ.
Abstract: The present invention relates to the fields of microbiology, molecular biology and protein biochemistry. More particularly, it relates to compositions and methods for analyzing and altering (e.g., enhancing or inhibiting) protein folding and solubility.
Abstract: The present invention relates to tomato plants that exhibit resistance to Botrytis cinerea and methods for developing new inbreds, hybrid, apomictic and genetically engineered tomato plants that possess resistance to Botrytis cinerea and having commercially desirable characteristics.
Type:
Application
Filed:
November 20, 2014
Publication date:
March 19, 2015
Applicants:
Cornell Research Foundation, Inc., Seminis Vegetable Seeds, Inc.
Inventors:
Brad Kane GABOR, Anna Julia FRAMPTON, Mauro BRAGALONI, Steven D. TANKSLEY
Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
Type:
Grant
Filed:
February 27, 2013
Date of Patent:
February 17, 2015
Assignees:
Cornell Research Foundation, Inc., Institute de Recherches Cliniques de Montreal
Inventors:
Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
Abstract: Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen (PSMA) or bind to and are internalized with PSMA. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of PSMA. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cells lines, each of which produces a monoclonal antibody recognizing extracellular domains of PSMA of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.
Abstract: The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and/or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes.